04:53:17 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



News for U:CHRS from 2023-03-30 to 2024-03-29 - 53 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-13 16:01U:CHRSNews ReleaseCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
2024-03-05 16:01U:CHRSNews ReleaseCoherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
2024-03-04 01:00U:CHRSNews ReleaseCoherus Completes Divestiture of Ophthalmology Franchise
2024-02-23 17:33U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2024-02-21 08:30U:CHRSNews ReleaseCoherus Announces U.S. Launch of UDENYCA ONBODY ¢ „ ¢ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2024-02-05 08:00U:CHRSNews ReleaseCoherus Amends Term Loan Agreement with Pharmakon Advisors, LP
2024-01-22 01:15U:CHRSNews ReleaseCoherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
2024-01-18 16:05U:CHRSNews ReleaseCoherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
2024-01-04 08:00U:CHRSNews ReleaseINOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI ¢ „ ¢ (toripalimab-tpzi)
2024-01-03 09:00U:CHRSNews ReleaseCoherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 08:29U:CHRSNews ReleaseCoherus Announces U.S. Launch of LOQTORZI ¢ „ ¢
2023-12-26 16:01U:CHRSNews ReleaseCoherus Announces FDA Approval of UDENYCA ONBODY ¢ „ ¢, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2023-12-22 17:00U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-12-11 08:30U:CHRSNews ReleaseCoherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
2023-12-07 17:56U:CHRSNews ReleaseCoherus BioSciences Announces CFO Transition Plans
2023-12-06 04:00U:CHRSNews ReleaseCoherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
2023-11-28 11:16U:CHRSNews ReleaseCoherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical As
2023-11-06 16:08U:CHRSNews ReleaseCoherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
2023-11-03 08:30U:CHRSNews ReleaseCoherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
2023-11-02 20:00U:CHRSNews ReleaseCoherus BioSciences to Participate at Upcoming November Investor Conferences
2023-10-30 18:00U:CHRSNews ReleaseCoherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
2023-10-27 15:07U:CHRSNews ReleaseCoherus and Junshi Biosciences Announce FDA Approval of LOQTORZI ¢ „ ¢ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
2023-10-24 19:41U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-10-14 12:30U:CHRSNews ReleaseCoherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2023-10-05 08:30U:CHRSNews ReleaseCoherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA ‚ ® ONBODY ¢ „ ¢
2023-10-04 08:30U:CHRSNews ReleaseCIMERLI ‚ ® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
2023-10-02 09:00U:CHRSNews ReleaseCoherus Applauds Congressional Designation of September 30th as Rare Cancer Day
2023-09-27 09:10U:CHRSNews ReleaseCoherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
2023-09-25 08:30U:CHRSNews ReleaseFDA Issues Complete Response Letter (CRL) for UDENYCA ‚ ® ONBODY ¢ „ ¢ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
2023-09-22 21:00U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-09-08 09:06U:CHRSNews ReleaseCoherus Completes Surface Oncology Acquisition
2023-09-01 16:01U:CHRSNews ReleaseCoherus BioSciences to Participate at Upcoming ‚  September Investor Conferences
2023-08-31 16:01U:CHRSNews ReleaseSurface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote ¢ € œFOR ¢ €  the Proposed Merger with Coherus BioSciences
2023-08-22 17:35U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-08-02 16:01U:CHRSNews ReleaseCoherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
2023-07-26 16:05U:CHRSNews ReleaseCoherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
2023-07-21 17:30U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-07-20 16:05U:CHRSNews ReleaseCoherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
2023-07-13 08:30U:CHRSNews ReleaseCoherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY ¢ „ ¢
2023-07-03 08:30U:CHRSNews ReleaseCoherus Launches YUSIMRY ¢ „ ¢, a Biosimilar of Humira ‚ ®, at $995 per Carton in U.S.
2023-06-26 21:08U:CHRSNews ReleaseCoherus BioSciences Announces New Employment Inducement Grants
2023-06-16 07:01U:CHRSNews ReleaseCoherus to Acquire Surface Oncology
2023-06-16 07:01U:CHRSNews ReleaseCoherus to Acquire Surface Oncology
2023-06-05 17:30U:CHRSNews ReleaseCoherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
2023-06-01 08:33U:CHRSNews ReleaseMark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY ¢ „ ¢, a HUMIRA ‚ ® biosimilar, available to patients
2023-06-01 08:30U:CHRSNews ReleaseCoherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY ¢ „ ¢ (adalimumab-aqvh) Launching in July 2023
2023-05-22 08:30U:CHRSNews ReleaseCoherus Announces U.S. Launch of UDENYCA ‚ ® Autoinjector
2023-05-16 06:50U:CHRSNews ReleaseCoherus Prices Public Offering of Common Stock
2023-05-15 16:01U:CHRSNews ReleaseCoherus Announces Proposed Public Offering of Common Stock
2023-05-08 16:05U:CHRSNews ReleaseCoherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
2023-05-04 16:30U:CHRSNews ReleaseCoherus BioSciences to Present at Upcoming Investor Conferences in May
2023-05-01 16:07U:CHRSNews ReleaseCoherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
2023-04-27 08:05U:CHRSNews ReleaseCoherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting